Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Compass Therapeutics Price Performance
Shares of NASDAQ:CMPX opened at $1.59 on Wednesday. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a market capitalization of $219.87 million, a price-to-earnings ratio of -4.30 and a beta of 1.40. The company's 50 day simple moving average is $2.67 and its 200 day simple moving average is $2.10.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). As a group, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. HC Wainwright upped their target price on Compass Therapeutics from $10.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, April 4th. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Jefferies Financial Group raised their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of "Buy" and an average price target of $13.38.
Get Our Latest Stock Analysis on Compass Therapeutics
Institutional Investors Weigh In On Compass Therapeutics
A number of hedge funds have recently made changes to their positions in CMPX. Barclays PLC boosted its position in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after buying an additional 112,614 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after acquiring an additional 356,352 shares in the last quarter. Geode Capital Management LLC grew its position in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock worth $4,251,000 after acquiring an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in Compass Therapeutics by 250.7% in the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock worth $58,000 after purchasing an additional 28,589 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company's stock valued at $75,000 after purchasing an additional 35,632 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
